FREE NEJM E-TOC    HOME   |   SUBSCRIBE   |   CURRENT ISSUE   |   PAST ISSUES   |   COLLECTIONS   |   Search Term  Advanced Search

Sign in | Get NEJM's E-Mail Table of Contents — Free | Subscribe

Previous Volume 334:1477-1478 May 30, 1996 Number 22 Next

	Since this article has no abstract, we have provided an extract of the first 100 words of the full text and any section headings.

	Full Text Purchase this article Add to Personal Archive Add to Citation Manager Notify a Friend E-mail When Cited Related Article by Barst, R. J.

To the Editor: Barst et al. (Feb. 1 issue)¹ report better clinical improvement and survival in 41 patients with primary pulmonary hypertension treated with a 12-week continuous intravenous infusion of epoprostenol (no deaths) than in 40 patients receiving conventional therapy (20 percent mortality). We wish to comment on the possible risks of treatment and the treatment strategy in this study.

The placement of a permanent catheter may lead to life-threatening complications, such as catheter-induced sepsis or thromboembolism (a total of five such events in this study). Selective pulmonary application of inhaled vasodilators may offer an attractive alternative, preventing the above . . . [Full Text of this Article]

References

This article has been cited by other articles:

• Hemnes, A. R., Zaiman, A., Champion, H. C. (2008). PDE5A inhibition attenuates bleomycin-induced pulmonary fibrosis and pulmonary hypertension through inhibition of ROS generation and RhoA/Rho kinase activation. Am. J. Physiol. Lung Cell. Mol. Physiol. 294: L24-L33 [Abstract] [Full Text]